Antoni Ribas, MD discusses cancer drugs targeting the PD1 signaling pathways
Interviewed by Steven E. Greer, MD
March 19, 2013
The upcoming ASCO meeting will be dominated by numerous presentations relating to new cancer drugs targeting the cell surface molecule called PD-L1, and the immune cell receptors PD1. Early Phase 1 data in non-small cell lung cancer, renal cancer, and melanoma demonstrated such impressive sustained tumor responses that they papers were published in the New England Journal of Medicine. Antoni Ribas, MD of the UCLA Jonsson Comprehensive Cancer Center is involved in trials testing some of these new molecules. In the video interview, he explains the mechanisms of action, reviews data published so far, and previews new data to be seen at ASCO.
Late Breaking Data, NEJM, Oncology, UCLA Med Ctr | apples49 | 
January 15, 2015 12:04 am
